Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganaxolone - Marinus Pharmaceuticals

Drug Profile

Ganaxolone - Marinus Pharmaceuticals

Alternative Names: CCD-1042; Ganaxalone-IV; gnx

Latest Information Update: 10 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Purdue Pharma
  • Developer Marinus Pharmaceuticals; Purdue Pharma
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antimigraines; Anxiolytics; Neuroprotectants; Pregnanes; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus; Infantile spasms; Fragile X syndrome; Epilepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Epilepsy
  • Phase II Fragile X syndrome; Lennox-Gastaut syndrome; Postnatal depression; Status epilepticus
  • Preclinical Angelman syndrome
  • No development reported Post-traumatic stress disorders
  • Discontinued Infantile spasms; Migraine; Neuropathic pain; Partial epilepsies

Most Recent Events

  • 04 Dec 2018 Long term efficacy data from a phase II trial in Epilepsy presented at the 72nd Annual Meeting of the American Epilepsy Association (AES-2018)
  • 25 Sep 2018 Marinus Pharmaceuticals completes enrolment in the phase II MAGNOLIA trial for Postnatal depression in USA
  • 19 Jun 2018 Phase-III clinical trials in Epilepsy (In children, In adolescents, In adults) in USA (PO, Capsule, Suspension) (NCT03572933) (EudraCT2018-001180-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top